All In Biotech

Drug Trial Radar · NCT05329194

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants With Severe Asthma Including Several Under-Studied Populations in the United States (PASSAGE)

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

286

Actual

Start

Apr 29, 2022

Primary completion

Oct 1, 2025

Study completion Oct 1, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.

Conditions

  • Asthma

Interventions

  • TezepelumabDrug

    Participants will be receiving subcutaneous injection of tezepelumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Asthma Exacerbation Rate (AAER)Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Mobile, Alabama

  • Research Site

    Gilbert, Arizona

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Rancho Mirage, California

  • Research Site

    Westminster, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Chicago, Illinois

  • Research Site

    Lexington, Kentucky

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Upper Marlboro, Maryland

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Ypsilanti, Michigan

  • Research Site

    Saint Paul, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Omaha, Nebraska

  • Research Site

    Hollis, New York

  • Research Site

    Horseheads, New York

  • Research Site

    Rochester, New York

  • Research Site

    Valhalla, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Toledo, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Altoona, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Warwick, Rhode Island

  • Research Site

    Greenville, South Carolina

  • Research Site

    Hendersonville, Tennessee

  • Research Site

    Fort Worth, Texas

  • Research Site

    McKinney, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Vancouver, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.